Yet Another Study Finds That Cannabis Use Is Not Independently Linked With IQ Decline

Marijuana researchCannabis use by teens is not independently linked with adverse changes in intelligence quotient or executive functioning, according to longitudinal data published online ahead of print in the journal Addiction.

A team of investigators from the United States and the United Kingdom evaluated whether marijuana use is directly associated with changes over time in neuropsychological performance in a nationally representative cohort of adolescent twins. Authors reported that “family background factors,” but not the use of cannabis negatively impacted adolescents’ cognitive performance.

They wrote: “[W]e found that youth who used cannabis … had lower IQ at age 18, but there was little evidence that cannabis use was associated with IQ decline from age 12 to 18. Moreover, although cannabis use was associated with lower IQ and poorer executive functions at age 18, these associations were generally not apparent within pairs of twins from the same family, suggesting that family background factors explain why adolescents who use cannabis perform worse on IQ and executive function tests.”

Investigators concluded, “Short-term cannabis use in adolescence does not appear to cause IQ decline or impair executive functions, even when cannabis use reaches the level of dependence.”

Their findings are consistent with those of several other studies – including those here, here, here, and here – finding that cannabis use alone during adolescence does not appear to have a significant, direct adverse effect on intelligence quotient.

widely publicized and still often cited New Zealand study published in 2012 in The Proceedings of the National Academy of Sciences reported that the persistent use of cannabis from adolescence to adulthood was associated with slightly lower IQ by age 38. However, a follow up review of the data published later in the same journal suggested that the observed changes were likely due to socioeconomic differences, not the subjects’ use of cannabis. A later study by the initial paper’s lead investigator further reported that the effects of persistent adolescent cannabis use on academic performance are “non-significant after controlling for persistent alcohol and tobacco use.”

Study: Alcohol Use, But Not Cannabis, Associated With Changes In Brain Structure

marijuana_seedlingAlcohol consumption is associated with negative changes in gray matter volume and in white matter integrity, while cannabis use is not, according to data published online ahead of print in the journal Addiction.

Investigators from the University of Colorado, Boulder and the Oregon Health & Science University evaluated neuroimaging data among adults (ages 18 to 55) and adolescents (ages 14 to 18). Authors identified an association between alcohol use and negative changes in brain structure, but identified no such association with cannabis.

“Alcohol use severity is associated with widespread lower gray matter volume and white matter integrity in adults, and with lower gray matter volume in adolescents,” they concluded. By contrast, “No associations were observed between structural measures and past 30-day cannabis use in adults or adolescents.”

Researchers acknowledged that their findings were similar to those of prior studies “suggesting that regionally specific differences between cannabis users and non-users are often inconsistent across studies and that some of the observed associations may actually be related to comorbid alcohol use.”

A 2015 brain imaging study published in The Journal of Neuroscience similarly reported that cannabis use was not positively associated with adverse changes in the brain, but that alcohol “has been unequivocally associated with deleterious effects on brain morphology and cognition in both adults and adolescents.”

Longitudinal data published in June in the British Medical Journal reported, “Alcohol consumption, even at moderate levels, is associated with adverse brain outcomes including hippocampal atrophy.”

An abstract of the study, “Structural Neuroimaging Correlates of Alcohol and Cannabis Use in Adolescents and Adults,” appears online here.

Study: Patients Report Substituting Cannabis For Opioids, Other Pain Medications

medical_mj_shelfPain patients report successfully substituting cannabis for opioids and other analgesics, according to data published online in the journal Cannabis and Cannabinoid Research.

Researchers from the University of California, Berkeley and Kent State University in Ohio assessed survey data from a cohort of 2,897 self-identified medical cannabis patients.

Among those who acknowledged having used opioid-based pain medication within the past six months, 97 percent agreed that they were able to decrease their opiate intake with cannabis. Moreover, 92 percent of respondents said that cannabis possessed fewer adverse side-effects than opioids. Eighty percent of respondents said that the use of medical cannabis alone provided greater symptom management than did their use of opioids.

Among those respondents who acknowledged having recently taken nonopioid-based pain medications, 96 percent said that having access to cannabis reduced their conventional drug intake. Ninety-two percent of these respondents opined that medical cannabis was more effective at treating their condition than traditional analgesics.

Authors concluded: “[M]ore people are looking at cannabis as a viable treatment for everyday ailments such as muscle soreness and inflammation. … [T]his study can conclude that medical cannabis patients report successfully using cannabis along with or as a substitute for opioid-based pain medication.”

The study’s conclusions are similar to those of several others, such as these herehereherehere, and here, finding reduced prescription drug use and spending by those with access to cannabis. Separate studies report an association between cannabis access and lower rates of opioid-related abuse, hospitalizations, traffic fatalities, and overdose deaths.

Full text of the study, “Cannabis as substitute for opioid-based pain medication: patient self-report,” appears online here.

Study: No Increase In Problematic Cannabis Use Following Passage Of Medical Marijuana Laws

no_marijuanaThe enactment of medical marijuana laws is not associated with increased rates of problematic cannabis use, according to data published online in the journal Addiction.

Columbia University investigators assessed cannabis use trends in states in the years following the passage of medicalization. They reported “no significant change in the prevalence of past-month marijuana use among adolescents or young adults (those ages 18 to 25)” following legalization. They also found no evidence of increased cannabis abuse or dependence by either young people or adults. States with largely unregulated medical programs were associated with increased self-reported use by adults age 26 and older, but states with stricter programs were not.

The study’s findings are consistent with those of numerous other papers reporting no uptick in youth marijuana use or abuse following medical marijuana regulation, including those here, here, here, here, here, and here. The findings contradict those of a recent, widely publicized paper in JAMA Psychiatry which speculated that medical marijuana laws may increase the prevalence of cannabis use disorder among adults.

An abstract of the study, “Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder,” is online here.

Review Identifies 140 Controlled Clinical Trials Related to Cannabis

Marijuana researchScientists have conducted over 140 controlled clinical trials since 1975 assessing the safety and efficacy of whole-plant cannabis or specific cannabinoids, according to a new literature review published in the journal Critical Reviews in Plant Sciences.

A pair of German researchers identified 140 clinical trials involving an estimated 8,000 participants. Of these, the largest body of literature focused on the use of cannabis or cannabinoids in the treatment of chronic or neuropathic pain. Authors identified 35 controlled studies, involving 2,046 subjects, assessing the use of marijuana or cannabinoids in pain management. In January, the National Academy of Sciences acknowledged that “conclusive or substantial evidence” exists for cannabis’ efficacy in patients suffering from chronic pain.

Cannabinoids have also been well studied as anti-emetic agents and as appetite stimulants. Researchers identified 43 trials evaluating marijuana or its components for these purposes, involving total 2,498 patients. They also identified an additional 14 trials examining the role of cannabis or cannabis-derived extracts in the treatment of multiple sclerosis.

Researchers also identified several additional trials evaluating the use of cannabis or cannabinoids for Crohn’s disease, Tourette’s syndrome, Parkinson’s disease, glaucoma, epilepsy, and various other indications.

A 2014 study published in the Journal of the American Medical Association reported that new drugs typically gain FDA approval on the basis of one or two pivotal clinical trials.

Full text of the study, “Medicinal uses of marijuana and cannabinoids,” appears online here.

Study: Medical Cannabis Use Associated With Improved Cognitive Performance, Reduced Use Of Opioids

Marijuana researchMedical cannabis administration is associated with improved cognitive performance and lower levels of prescription drug use, according to longitudinal data published online in the journal Frontiers in Pharmacology.

Investigators from Harvard Medical School, Tufts University, and McLean Hospital evaluated the use of medicinal cannabis on patients’ cognitive performance over a three-month period. Participants in the study were either naïve to cannabis or had abstained from the substance over the previous decade. Baseline evaluations of patients’ cognitive performance were taken prior to their cannabis use and then again following treatment.

Researchers reported “no significant decrements in performance” following medical marijuana use. Rather, they determined, “[P]atients experienced some improvement on measures of executive functioning, including the Stroop Color Word Test and Trail Making Test, mostly reflected as increased speed in completing tasks without a loss of accuracy.”

Participants in the study were less likely to experience feelings of depression during treatment, and many significantly reduced their use of prescription drugs. “[D]ata revealed a notable decrease in weekly use across all medication classes, including reductions in use of opiates (-42.88 percent), antidepressants (-17.64 percent), mood stabilizers (-33.33 percent), and benzodiazepines (-38.89 percent),” authors reported – a finding that is consistent with prior studies.

Patients in the study will continue to be assessed over the course of one-year of treatment to assess whether these preliminary trends persist long-term.

Full text of the study, “Splendor in the grass? A pilot study assessing the impact of marijuana on executive function,” appears online here.

Study: Vaporized, Low-Potency Cannabis Mitigates Neuropathic Pain

The administration of vaporized, low THC cannabis is associated with reduced pain in subjects with neuropathy, according to clinical trial data published online by The Journal of Pain.

Investigators at the University of California, Davis Medical Center conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic efficacy of vaporized cannabis in 39 subjects, the majority of whom were experiencing neuropathic pain despite traditional treatment. Subjects inhaled cannabis of either moderate THC (3.53 percent), low dose THC (1.29 percent), or zero THC (placebo). Subjects continued to take all other concurrent medications as per their normal routine during the 3- to 4-week study period. Spontaneous pain relief, the primary outcome variable, was assessed by asking participants to indicate the intensity of their current pain on a 100-mm visual analog scale (VAS) between 0 (no pain) and 100 (worst possible pain).

Researchers reported: “Both the low and medium doses proved to be salutary analgesics for the heterogeneous collection of neuropathic pain conditions studied. Both active study medications provided statistically significant 30% reductions in pain intensity when compared to placebo.”

They concluded: “Both the 1.29% and 3.53% vaporized THC study medications produced equal antinociception at every time point. … [T]he use of low doses could potentially be prescribed by physicians interested in helping patients use cannabis effectively while minimizing cognitive and psychological side effects. Viewed with this in mind, the present study adds to a growing body of literature supporting the use of cannabis for the treatment of neuropathic pain. It provides additional evidence of the efficacy of vaporized cannabis as well as establishes low-dose cannabis (1.29%) as having a favorable risk-benefit ratio.”

Previous clinical trials have indicated that inhaled cannabis can safety and effectively relieve various types of pain, particularly neuropathy — a hard-to-treat nerve condition often associated with cancer, HIV, spinal cord injury, diabetes, multiple sclerosis, and other conditions. These include the following double-blind, placebo-controlled (FDA gold-standard) studies:

Ware et al. 2010. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 182: 694-701.

Wilsey et al. 2008. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. Journal of Pain 9: 506-521.

Ellis et al. 2008. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 34: 672-80.

Abrams et al. 2007. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68: 515-521.

Wallace et al. 2007. Dose-dependent Effects of Smoked Cannabis on Capsaicin-induced Pain and Hyperalgesia in Healthy Volunteers Anesthesiology 107: 785-796.

Separate clinical trial data also reports that inhaled “cannabis augments the analgesic effect of opioids” and therefore “may allow for opioid treatment at lower doses with fewer side effects.”

Since 1999, US sales of opiate drugs have tripled in number and in 2010, a record-setting 254 million prescriptions for opioids were filled in the United States — enough to medicate every American adult around the clock for a month. (In particular, the manufacturing of the drug Oxycodone has increased from 8.3 tons in 1997 to 105 tons in 2011, an increase of 1,200 percent.) Overdose deaths from the use of prescription painkillers are also now at record levels, totaling some 15,000 annually — more than triple the total a decade ago.

Full text of the study, “Low-dose vaporized cannabis significantly improves neuropathic pain,” appears in The Journal of Pain.

My first medical marijuana grow journal

My first grow room. This is the day after my two girls, Thelma and Louise were born. Thelma is an OG Lavender and Louise is a Bubba Kush. I’m going to try and capture a video journal every two days or so while I’m on my medication. I have my medical marijuana recommendation from a doctor and I live in California. Everything here is totally legal as of the date posted.
Video Rating: 4 / 5

Cenk Uygur on a California couple facing 5 years in prison after being raided for growing medical marijuana despite the fact it’s legal in California. Cenk also shares findings from the National Cancer Institute on the medical benefits of marijuana. Subscribe: bit.ly TYT Mobile: bit.ly On Facebook: www.facebook.com On Twitter: twitter.com www.theyoungturks.com FREE Movies(!): www.netflix.com Read Ana’s blog and subscribe at: www.examiner.com Read Cenk’s Blog: www.huffingtonpost.com

Login | Register

Copyright Top Nug © All Rights Reserved · Top Nug Theme by Ame

PIXSELL8 Pixel Count Remaining